Landscape Capital Management L.L.C. Takes $1.61 Million Position in Globus Medical, Inc. $GMED

Landscape Capital Management L.L.C. acquired a new stake in Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,405 shares of the medical device company’s stock, valued at approximately $1,607,000.

A number of other large investors also recently modified their holdings of GMED. Kestra Advisory Services LLC lifted its position in Globus Medical by 37.7% during the fourth quarter. Kestra Advisory Services LLC now owns 8,575 shares of the medical device company’s stock valued at $749,000 after purchasing an additional 2,349 shares during the last quarter. Johnson Investment Counsel Inc. bought a new stake in shares of Globus Medical in the 4th quarter worth approximately $214,000. Inspire Advisors LLC bought a new stake in shares of Globus Medical in the 4th quarter worth approximately $547,000. UMB Bank n.a. lifted its holdings in shares of Globus Medical by 23.1% in the 4th quarter. UMB Bank n.a. now owns 1,512 shares of the medical device company’s stock worth $132,000 after acquiring an additional 284 shares during the last quarter. Finally, Commerce Bank lifted its holdings in shares of Globus Medical by 4.1% in the 4th quarter. Commerce Bank now owns 10,465 shares of the medical device company’s stock worth $914,000 after acquiring an additional 411 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors.

Globus Medical Trading Down 3.9%

GMED stock opened at $77.25 on Tuesday. The firm’s 50-day moving average price is $85.56 and its two-hundred day moving average price is $88.00. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 1.66 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million for the quarter, compared to analysts’ expectations of $740.35 million. During the same quarter in the previous year, the company earned $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Equities analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GMED. Needham & Company LLC boosted their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Wells Fargo & Company lowered their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Barclays lifted their target price on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Finally, Piper Sandler decreased their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating on the stock in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Insider Activity

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 18.38% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.